Loading…
← CockpitCompetitor Analysis › PCR.WA PCC Rokita Spolka AkcyjnaOpen in the cockpit ↗

PCC Rokita Spolka AkcyjnaPCR.WACompetitor analysis, valuation and peers

Poland · PLN·Materials›Chemicals: Specialty
Momentum weak 30
Mkt cap
$314M
US dollars, full cap
Free float
17%
of shares outstanding
$/day
$85,102
20-day average traded
Fwd P/E
10.0×
forward earnings
ROIC−WACC
-5.7 pp
WACC 9.9%
Hurdle
+4 pp
Req g minus delivered
Next earnings
127 days
25 Mar 2027
Close · PLNPLN 62.30
1D+0.5%
1W0.0%
1M-1.4%
3M-8.4%
6M-10.6%
YTD+1.6%
1Y-9.2%
ATR %1.9%
52w lowhigh16.3% off high

What PCC Rokita Spolka Akcyjna does

Employees: 1,370

PCC Rokita Spolka Akcyjna at a glance

Size PCC Rokita Spolka Akcyjna (PCR.WA) is a Poland Materials company (Chemicals: Specialty) with a market value of $314M, the 78th largest of 82 Poland companies the cockpit tracks. Shares closed at PLN 62.30 on 18 Nov 2026.

Performance Over six months the shares fell 10.6%, against -30.4% for the median peer and +14.0% for the Poland market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue fell 0.9% over the last twelve months (peer median +12.5%); the operating margin is 5.0% (peer median 7.5%).

Valuation It trades at 10.0× forward earnings against a peer median of 9.8× (4th most expensive of 9).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 5.7 points below its cost of capital (9.9% WACC).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026PCR.WA 90Peer median 68
Six months, rebased to 100: PCC Rokita Spolka Akcyjna against the median of its 20 peers (local-currency closes).

PCC Rokita Spolka Akcyjna financials

Reported figures in PLN; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenuePLN 1.84BPLN 1.80BPLN 1.95BPLN 2.39BPLN 3.14B
Revenue growth—-8%-18%-24%—
Gross profitPLN 353MPLN 326MPLN 391MPLN 583MPLN 1.15B
EBITDAPLN 243MPLN 188MPLN 278MPLN 459MPLN 993M
Net incomePLN 113MPLN 61.5MPLN 143MPLN 268MPLN 675M
Free cash flowPLN 177MPLN 119MPLN 145MPLN 265MPLN 535M
Capital expenditurePLN 96.8MPLN 152MPLN 129MPLN 216MPLN 229M
Total debtPLN 499MPLN 545MPLN 640MPLN 599MPLN 643M

Quarterly statements and history in the cockpit →

PCC Rokita Spolka Akcyjna competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-30%-20%-10%0%4022161000600319603172104830PREMEXPLN4027TRUALT002442178920002136300538603722300437301281340570POLYPLEX63094970PCR.WA6-month return →1-month return →
Up and to the right = strong over both horizons. PCC Rokita Spolka Akcyjna is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%7.5×10×12.5×15×4022104830TRUALT178920340570630941094970PCR.WARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. PCC Rokita Spolka Akcyjna is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%4022104830178920300437340570POLYPLEX41094970PCR.WAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. PCC Rokita Spolka Akcyjna is the large dot.

PCC Rokita Spolka Akcyjna competitors and peer comparison

How PCC Rokita Spolka Akcyjna compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

PCC Rokita Spolka Akcyjna against its 20 peers (data as of 18 Nov 2026)
MeasurePCR.WAPeer medianRank in peer set
1-month return-1.4%-13.0%4th highest of 21
6-month return-10.6%-30.4%6th highest of 21
Distance from 52-week high-16.3%-46.5%2nd highest of 21
Revenue growth (TTM)-0.9%+12.5%7th lowest of 21
Operating margin5.0%7.5%8th lowest of 21
Forward P/E10.0×9.8×4th most expensive of 9
Growth the price implies (Req g, 7 yrs)8.4%7.5%4th most demanding of 9
Growth delivered (Del g)+4.1%+5.4%5th highest of 9
Hurdle (Req g minus delivered)+4.4 pp+0.0 pp4th most demanding of 9
ROIC minus cost of capital-5.7 pp-2.2 pp7th lowest of 21
EV / EBITDA6.6×6.3×6th most expensive of 13
Net debt / EBITDA1.4×0.1×4th most indebted of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
PCC Rokita Spolka Akcyjna PCR.WAPoland$314M-11%-1%5%10.0×8.4%+4.1%
Rasa Industries,Ltd 4022.TJapan$315M-38%+16%12%9.6×7.7%+10.5%
Aekyung Chemical 161000.KSSouth Korea$313M-40%+16%3%n/an/an/a
Weifang Yaxing Chemical 600319.SSChina$311M-32%-1%-9%n/an/an/a
Zhejiang Wanfeng Chemical 603172.SSChina$317M-30%+17%11%n/an/an/a
WONIK Materials 104830.KSSouth Korea$317M-31%+17%18%7.2×-8.3%+3.1%
Premier Explosives PREMEXPLN.NSIndia$311M+3%-9%5%n/an/an/a
Tayca 4027.TJapan$311M+20%+17%6%n/an/an/a
Trualt Bioenergy TRUALT.NSIndia$309M-27%-5%14%9.9×n/an/a
Longxing Technology 002442.SZChina$319M-29%+7%1%n/an/an/a
PI Advanced Materials 178920.KSSouth Korea$307M-54%-2%22%9.0×-10.8%+0.1%
Anhui Annada Titanium Industry 002136.SZChina$306M-35%+12%2%n/an/an/a
Shenzhen Tongyi Industry 300538.SZChina$305M-34%-31%-3%n/an/an/a
Wuxi Acryl Technology 603722.SSChina$327M-43%+34%-15%n/an/an/a
Henan Qingshuiyuan Technology 300437.SZChina$327M-40%+13%-1%n/a26.9%-6.8%
Shandong Keyuan Pharmaceutical 301281.SZChina$298M-18%+33%15%n/an/an/a
T&L 340570.KSSouth Korea$331M-1%-5%34%8.7×-15.9%+32.2%
Polyplex POLYPLEX.NSIndia$332M+11%+16%6%n/a17.3%+7.6%
Tomoe Engineering 6309.TJapan$333M+3%+2%9%12.5×n/an/a
Stella Chemifa 4109.TJapan$333M-28%+9%11%14.9×7.2%+2.3%
Toyo Gosei 4970.TJapan$335M-58%+21%14%11.9×11.9%+9.1%

Questions

Which companies are PCC Rokita Spolka Akcyjna's closest peers?
The cockpit's peer set: Rasa Industries,Ltd (4022.T), Aekyung Chemical (161000.KS), Weifang Yaxing Chemical (600319.SS), Zhejiang Wanfeng Chemical (603172.SS), WONIK Materials (104830.KS), Premier Explosives (PREMEXPLN.NS), Tayca (4027.T), Trualt Bioenergy (TRUALT.NS).
Is PCC Rokita Spolka Akcyjna expensive compared with its peers?
On forward p/e it trades at 10.0× against a peer median of 9.8×, 4th most expensive of 9 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has PCC Rokita Spolka Akcyjna stock performed?
Over six months to 18 Nov 2026 the shares returned -10.6% against -30.4% for the median peer; over one year -9.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.